Profile: Keryx Biopharmaceuticals focuses on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, that include diabetes & cancer. We develop Zerenex™, an oral, inorganic, iron-based compound, with a capacity to bind to phosphorous and form nonabsorbable complexes. Sulonex™ reduces urinary protein excretion in patients with diabetic nephropathy.